The city of Petrópolis, Brazil, is set to begin immunization against Respiratory Syncytial Virus (RSV), which is the main cause of bronchiolitis in infants. This initiative will start on Monday, December 2, and targets infants born prematurely, as well as children with comorbidities who were delivered at the Alcides Carneiro Hospital. The monoclonal antibody Nirsevimab, recommended by Brazil's Ministry of Health, will be administered to these vulnerable groups in order to reduce the incidence of bronchiolitis.

The vaccination strategy was unveiled on February 25 during a meeting held by the Epidemiological Surveillance team with pediatric and neonatal professionals from the hospital. The program will specifically cater to premature babies who are 36 weeks and six days gestational age or younger and children up to 1 year, 11 months, and 29 days of age with existing health conditions. Mayor Hingo Hammes confirmed that the municipality will adhere strictly to the criteria set by the Ministry of Health, indicating a structured approach to this important public health initiative.

This campaign is anticipated to significantly decrease the number of bronchiolitis cases in this vulnerable population. By focusing on high-risk groups, the local government aims to enhance overall healthcare outcomes for infants in the region, ultimately benefiting both the children and their families. This move reflects a broader commitment to preventive healthcare measures in Brazil, particularly regarding childhood illnesses that pose serious health risks.